Company intelligence / Profile preview

BridgePoint Medical

Plymouth, Minnesota, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

BridgePoint Medical developed and commercialized specialized catheter-based devices for crossing chronic total occlusions in coronary and peripheral arteries. Their CrossBoss™ CTO Crossing Catheter and Stingray™ CTO Re-entry System received CE Mark clearance in Europe and FDA clearance in the US. Clinical studies demonstrated their effectiveness for treating complex vascular blockages.

The company was acquired by Boston Scientific Corporation in September 2012.

Prior to acquisition, they had also entered into an exclusive licensing agreement with Covidien for certain technologies.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Covidien (exclusive license agreement on some technologies prior to acquisition)

Beyond the preview

Go deeper on BridgePoint Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BridgePoint Medical.

Explore the full profile